AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
Investor's Business Daily on MSN9h
AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter BeatAstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with locally ...
The tenosynovial giant cell tumor (TGCT) trial hit its primary endpoint, teeing up an option decision that could establish ...
AstraZeneca and Daiichi Sankyo have submitted a new biologics license application (BLA) for accelerated approval for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback